Policy & Regulation


  • Makary FDA
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    FDA’s new mission to speed drug reviews

    FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.

    By June 30, 2025
  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    3 of the year’s most notable FDA nods

    The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

    By June 27, 2025
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • A person in a business suit looks past two other people standing with their backs to the camera.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip

    CDC panel, newly remade by RFK Jr., questions vaccine evidence

    New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

    By Delilah Alvarado • June 26, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Grandbrothers via Getty Images
    Image attribution tooltip

    Biopharma is on edge about NIH funding cuts and what the future holds for research

    Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

    By June 26, 2025
  • Retro microphones for press conference or interview and old TV on table front gradient aquamarine background
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    Is DTC pharma advertising coming to an end?

    A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

    By June 18, 2025
  • man in a navy suit with a red tie sits hands crossed at a desk with a microphone
    Image attribution tooltip
    Kayla Bartkowski via Getty Images
    Image attribution tooltip

    FDA to speed reviews for drugs supporting ‘national interests’

    A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

    By Jonathan Gardner • June 18, 2025
  • diversity hands pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a patient group tackled research diversity for one disease and triggered change for pharma

    A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

    By June 17, 2025
  • Sarah Sanders in white stands at podium with three American flags in the background
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Locked in a federal stalemate, states take PBM reform into their own hands

    Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

    By June 16, 2025
  • doctor piggy bank 340B
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Will pharma finally score a policy win for 340B?

    The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

    By Kelly Bilodeau • June 16, 2025
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Pharma’s wins and losses in the budget bill

    Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

    By June 11, 2025
  • Road sign symbolizing decision between vaccine or no vaccine
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    COVID vax restrictions may not hamper uptake — but the market is still under pressure

    If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

    By Alexandra Pecci • June 10, 2025
  • A person in a dark business suit sits at a desk with a microphone.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA’s Elsa AI is here, and the industry has questions

    The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

    By June 5, 2025
  • sad face bag
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech CEO confidence hits rock bottom amid policy shifts

    A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

    By June 4, 2025
  • A handful of syringes containing COVID-19 vaccine doses rest in a cardboard tray.
    Image attribution tooltip
    Thomas Lohnes via Getty Images
    Image attribution tooltip

    COVID’s remaining biotech contenders navigate a dwindling market

    With policy and funding evolving, companies are being forced to rethink strategies. 

    By Kelly Bilodeau • June 2, 2025
  • president trump smiling with robert kennedy jr.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    The MAHA agenda won’t include expanding GLP-1 coverage — for now

    Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

    By June 2, 2025
  • President Donald Trump stands at podium with Robert F. Kennedy Jr. on his left side
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    What’s next for Trump’s ‘most favored nation’ policy?

    HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.

    By May 27, 2025
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The placebo effect: How a new FDA rule could pile more strain onto vaccine developers

    The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.

    By Alexandra Pecci • May 20, 2025
  • Donald Trump (C) speaks during a press conference in the Roosevelt Room of the White House with health agency leaders on either side
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    With the third round of Medicare price negotiations on the way, here’s how the policy is shifting

    HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.  

    By May 19, 2025
  • globe syringes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tracking a moving target: Drugmakers brace for a looming tariff impact

    With policies in flux, companies seek to be proactive and understand their supply chain.

    By Kelly Bilodeau • May 19, 2025
  • Trump RFK EO
    Image attribution tooltip
    Andrew Harnik/ via Getty Images
    Image attribution tooltip

    Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.

    The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.

    By May 14, 2025
  • MAHA
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

    Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

    By Alexandra Pecci • May 13, 2025
  • Robert F. Kennedy Jr.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    RFK Jr.’s autism fixation hearkens back to his stance on vaccines

    The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

    By May 9, 2025
  • FDA headquarters sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Prasad’s FDA appointment pressures cell and gene therapy stocks

    A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

    By Ben Fidler • May 7, 2025
  • red and blue pill full of social media icons against yellow backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With TV ads under threat, here’s how pharma can leverage social media

    RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

    By May 7, 2025
  • Joaquin Duato
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

    Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

    By May 6, 2025